Capital floods longevity clinics but EU rules restrict top therapies

Billions of dollars are now flowing into start-ups focused on cell rejuvenation, young plasma, and telomere repair. The surge in capital reflects a booming wellness sector that has moved far beyond traditional retreats into the realm of bioscience. For investors and medical tourists alike, the promise of extending human life has become a serious commercial proposition.

However, European medi-spas are hitting a regulatory wall. Harvesting stem cells from umbilical cords is only permitted in Mexico, South Korea, Japan, and India. This means elite European facilities such as Clinique La Prairie, Lanserhof, Mount Med, and Sha's Alicante outpost cannot offer these imported treatments, forcing them to rely on culturing a patient's own cells instead.

The financial stakes of this scientific race are evident in recent pharmaceutical deals. Alkahest, a company researching the regenerative qualities of young blood, was acquired by Grifols for about £110 million in 2020. More recently, Altos Labs raised roughly £2.2 billion to pursue gene manipulation aimed at making cells grow younger. These figures underscore the market's expectation that anti-ageing science will soon yield profitable therapies.

In the shorter term, the longevity industry is closely watching the GLP-1 family of drugs, including Mounjaro, Ozempic, and Wegovy. Dr Jair Olivares, clinical director at Sha Mexico, predicts these peptides will eventually be used “in the prevention of inflammation, and that’s a game changer. This is the drug of the future.” Yet European medical professionals remain cautious. Alexander Papp, chief medical officer of Mount Med in Austria, warns that patients should avoid weight-loss drugs “having massive effects on the pancreatic system, on depression, on enzyme levels” in favour of diet and exercise.

For now, much of the cutting-edge biohacking exists in a regulatory grey area. Bryan Johnson, the movement's most prominent figure with two million Instagram followers, underwent gene therapy at a clinic in a special economic zone in Honduras. “There’s no stopping humans from taking things and doing things without evidence,” Johnson says. “They’ve been doing that for as long as existence.”

Until experimental therapies secure widespread clinical approval, European clinics must balance high client demand with medical safety. “Of course, we are going to offer you things that you’ll never see in hospitals,” Dr Olivares says. “But we want to offer you things that are going to be safe.” Despite the billions chasing immortality, the European market's immediate future still relies on the traditional fundamentals of diet, sleep, and exercise.